tirzepatide injection thurmont Injections Tirzepatide - CoreAge Rx

In the SURPASS clinical trial program, tirzepatide demonstrated HbA1c reductions of 1.9% to 2.4% at the 15 mg dose, and in the SURPASS-2 trial specifically showed greater efficacy compared to semaglutide 1 mg

Chen, Z., Young, T

This can result in potential side effects and other risks

Avoiding high-fat foods during the adaptation phase helps, as fat slows digestion further and can worsen discomfort

Long-term cardiovascular outcomes data from the ongoing SURPASS-CVOT trial will provide more comprehensive safety and efficacy information for extended treatment durations

Important Safety Information for Toujeo U-300 (insulin glargine) injection SoloStar and Toujeo Max SoloStar Toujeo SoloStar and Toujeo Max SoloStar are single-patient-use prefilled insulin pens